Showing 1221-1230 of 1779 results for "".
- Vehicles, Infectious Disease, and Acne Updates from Day 2 at DERM2019https://practicaldermatology.com/news/vehicles-infectious-disease-and-acne-updates-from-day-2-at-derm2019/2460099/The DERM2019 NP/PA CME Conference continued to delight audiences with esteemed faculty presenters, including those who presented Friday, including April Armstrong, David Cohen, Kara Gooding, Joseph Gorelick, Julie Harper, Jayme Heim, George Keough, Leon Kircik, Kristine Kucera, Gilly Munavalli, T
- Psoriasis, Psoriatic Arthritis, and AD Updates from Day 1 at DERM2019https://practicaldermatology.com/news/psoriasis-psoriatic-arthritis-and-ad-updates-from-day-1-at-derm2019/2460098/The first day of the DERM2019 NP/PA CME Conference kicked off with a bang! Exciting talks and lively panel discussions from April Armstrong, David Cohen, Adam Friedman, Kara Gooding, and Joe Gorelick were the mainstay of the day. Psoriasis Pathogenesis and Treatment T
- AAD Honors Chicago Doctors for Multidisciplinary Approach to Eczema Carehttps://practicaldermatology.com/news/aad-honors-chicago-doctors-for-multidisciplinary-approach-to-eczema-care/2460094/Dermatologist Jonathan Silverberg, MD, PhD, MPH, FAAD, and sleep neurologist Hrayr Attarian, MD, were named Patient Care Heroes by the American Academy of Dermatology for teaming up to provide coordinated, multidisciplinary care to patients with eczema. Both physicians practice medicine
- New to SENTE BOD: Clint Carnell and Clement Gingrashttps://practicaldermatology.com/news/new-to-sente-bod-clint-carnell-and-clement-gingras/2460093/SENTÉ has appointed Clint Carnell and Clement Gingras to its Board of Directors effective immediately. "We are thrilled to have both Clint and Clement join the SENTÉ team," says Faheem Hasnain, Chairman of t
- Topical Collagen Powder May Be Effective for Wound Closurehttps://practicaldermatology.com/news/collagen-may-be-effective-for-wound-closure/2460091/Collagen powder is as effective in managing skin biopsy wounds as primary closure with non-absorbable sutures, according to a first-of-its-kind study published in the Journal of Drugs in Dermatology. Researchers investigated the efficacy of topical collagen powder compared
- Positive Results Seen in Phase 3 FMX101 Acne Studyhttps://practicaldermatology.com/news/study-positive-results-see-in-phase-3-fmx101-acne-study/2460088/In patients with moderate to severe acne vulgaris, treatment with FMX101 4% topical minocycline foam is well tolerated and effective for reducing the number of inflammatory lesions, according to results of a randomized trial published in the Journal of the American Academy of Dermatology
- LEO Pharma Completes Acquisition of Bayer’s Prescription Dermatology Businesshttps://practicaldermatology.com/news/leo-pharma-completes-acquisition-of-bayers-prescription-dermatology-business/2460086/LEO Pharma and Bayer announced the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO Pharma. The companies first announced the proposed transaction on July 31, 2018 and completed the first step of the acquisition
- Phase 3b/4 Study ANSWERs Rosacea Therapy Questionshttps://practicaldermatology.com/news/phase-3b4-study-answers-rosacea-therapy-questions/2460082/Results of the phase 3b/4 ANSWER study, recently published onlinein the Journal of the American Academy of Dermatology, show that concomitant use of Oracea Capsules and Soolantra Cream provided significan
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en